Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.
about
Molecular Targeted Therapies of Aggressive Thyroid CancerUpdate: the status of clinical trials with kinase inhibitors in thyroid cancerAberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancerTargeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.Peroxisome proliferator-activated receptor-γ agonist troglitazone suppresses transforming growth factor-β1 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro.A new dawn for the use of thiazolidinediones in cancer therapy.Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?Antihyperglycaemic therapies and cancer risk.PPARγ ligands and their therapeutic applications: a patent review (2008 - 2014).Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.Adiponectin and its receptor signaling: an anti-cancer therapeutic target and its implications for anti-tumor immunity.Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer.Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration.The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer.Personalization of targeted therapy in advanced thyroid cancer.Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells.Optimal combination of treatment modality to increase survival in patients with anaplastic thyroid carcinoma: A STROBE compliant retrospective study.
P2860
Q26774734-4D5FEAD0-1420-45EE-A8A7-F18445BB7062Q33570056-A914DD71-B13B-4290-AAAC-B73AAC4A60E0Q35578234-F63F2C12-8393-477F-A629-0F84660BE2B4Q35622067-B661DEAF-885F-4AE7-83A9-08F4344E15C4Q36027160-30D8461F-4278-48DD-9E8A-F41292262100Q37086070-D3EBBE00-15B7-4A26-ACE1-AA5A1CA56831Q37088201-3EE68DB8-993F-4BF7-BE5C-2CCA3ABFC9ECQ37227987-1E9433A7-739F-4007-B902-88C061FA60E5Q38193545-D4617A7E-F0C1-4137-B144-32B911C7C5BCQ38217116-230BA34E-785D-4A6E-A363-C6FE720C81D6Q38250719-E0B6BDE1-41ED-412C-868C-2BB25B997793Q38270503-7392FA32-9A07-457B-B0A1-B50AFDF64C07Q38441002-A37828E7-F719-4385-A3AE-37462541FB27Q38465754-497C1ED7-2FDE-4566-9A1F-8EEC42945CC3Q38657760-7E6E208A-7B35-4641-AD61-8E283DBF2105Q38754489-6D2C86E0-B15D-4C38-8D84-A6ADF38DFFCEQ38798863-528CEDB4-411B-49AE-831B-A669D491CB9CQ38815256-59C79557-7759-4D1E-AEB9-10416AC35B83Q38979602-07F792D4-84E3-4AB5-9E53-FCBBA750DCFCQ39082422-24F3F17A-5991-4DA1-A28B-7D6AA5DF6CD0Q40922523-E66A8CEE-969D-4AF5-8884-9925D36A8A9BQ52638921-DCF88802-187B-427B-A8CF-327AB6CBB23FQ55406601-17C9E16F-3A09-4E08-B32A-0AF74E1AC768
P2860
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Efatutazone, an oral PPAR-γ ag ...... f a multicenter phase 1 trial.
@en
type
label
Efatutazone, an oral PPAR-γ ag ...... f a multicenter phase 1 trial.
@en
prefLabel
Efatutazone, an oral PPAR-γ ag ...... f a multicenter phase 1 trial.
@en
P2093
P2860
P356
P1476
Efatutazone, an oral PPAR-γ ag ...... f a multicenter phase 1 trial.
@en
P2093
A W Gramza
J A Copland
J P Klopper
J T Wadsworth
L A Marlow
M E Menefee
M G Heckman
P2860
P304
P356
10.1210/JC.2013-1106
P407
P577
2013-04-15T00:00:00Z